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Manuel Arias, MD, PhD, Miguel A. González-Gay, MD, PhD,* and Ricardo Blanco, MD, PhD*Abstract: The severity of clinical features and the outcomes in previous
series of patients reported with Henoch-Schönlein purpura (HSP) vary
greatly, probably due to selection bias. To establish the actual clinical spec-
trum of HSP in all age groups using an unselected and wide series of
patients diagnosed at a single center, we performed a retrospective review
of 417 patients classified as having HSP according to the criteria proposed
byMichel et al. Of 417 patients, 240 were male and 177 female, with a me-
dian age at the time of disease diagnosis of 7.5 years (interquartile range
[IQR], 5.3–20.1 yr). Three-quarters of the patients were children or young
people aged 20 years or younger (n = 315), and one-quarter were adults
(n = 102). The most frequent precipitating events were a previous infection
(38%), usually an upper respiratory tract infection, and/or drug intake
(18.5%) shortly before the onset of the vasculitis. At disease onset the most
common manifestations were skin lesions (55.9%), nephropathy (24%),
gastrointestinal involvement (13.7%), joint symptoms (9.1%), and fever
(6.2%). Cutaneous involvement occurring in all patients, mainly purpuric
skin lesion, was the most common manifestation when the vasculitis was
fully established, followed by gastrointestinal (64.5%), joint (63.1%), and
renal involvement (41.2%). The main laboratory findings were leukocyto-
sis (36.7%), anemia (8.9%), and increased serum IgA levels (31.7%). The
most frequent therapies used were corticosteroids (35%), nonsteroidal
antiinflammatory drugs (14%), and cytotoxic agents (5%). After a median
follow-up of 12 months (IQR, 2–38 mo), complete recovery was observed
in most cases (n = 346; 83.2%), while persistent, usually mild, nephropathy
was observed in only 32 (7.7%) cases. Relapses were observed in almost
a third of patients (n = 133; 31.9%).
In conclusion, although HSP is a typical vasculitis affecting children and
young people, it is not uncommon in adults. The prognosis is favorable
in most cases, depending largely on renal involvement.
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INTRODUCTION
The systemic vasculitides are a complex group of conditionscharacterized by inflammatory involvement of vessels leading
to different but often overlapping manifestations.19 Henoch-
Schönlein purpura (HSP) is a systemic vasculitis clinically
characterized by the classic clinical triad consisting of palpable
purpura, joint symptoms, and abdominal pain.41 However, renal
involvement is the most serious complication of this vasculi-
tis.18,20,36,40,41 The etiology remains unknown,42 but precipitating
events, such as upper respiratory tract infections (URTIs) and/or
drug intake, have been associated with the development of
HSP.8,12–14,17,20,31 The pathogenesis of HSP also remains un-
known,42 although several authors have confirmed the potential
implication of an aberrant glycosylation of the hinge region
of IgA1.39,40,42
Histologically, HSP is characterized by infiltration of the small
blood vessels by polymorphonuclear leukocytes and the presence
of leukocytoclasia. Immunofluorescence staining of tissues may
reveal the presence of IgA-dominant immune deposits in the walls
of the small vessels (that is, capillaries, venules, arterioles, or in the
renal glomeruli).3,15,19,20,25,26,48
HSP is typically a childhood disease.6,41 While in children it
is often a self-limited and benign disease,4–6,45 HSP in adults has
been described as associated with worse clinical features and poor
outcome.3,12,13 The severity of clinical features and outcomes
vary greatly. There are a number of potential explanations for
these disparate results. First, the criteria used to define HSP often
vary from one series to another. Second, skin biopsy was consid-
ered an inclusion criterion in some studies; however, in clinical
practice biopsy is often avoided for cases with mild vasculitic syn-
drome, usually younger patients. Third, patients in many studies
were selected patients seen in referral centers, or even seen in ne-
phrology referral services due to renal complications, and there-
fore the clinical spectrum of the disease in some series was
more severe than in others.1,2,7,11,23,27,32,35,37,43,44
Considering these limitations of previous studies, our aim
was to establish the actual clinical spectrum and outcome of
HSP in all age groups, using for this purpose an unselected and
wide series of consecutive patients with HSP diagnosed at a
single center.
PATIENTS AND METHODS
We reviewed the clinical records of all patientswith a diagno-
sis of cutaneous vasculitis seen in our center (Hospital UniversitarioMedicine • Volume 93, Number 2, March 2014
thorized reproduction of this article is prohibited.
TABLE 1. Criteria for Differentiating Henoch-Schönlein




Slightly elevated purpuric rash over
1 or more areas of the skin
not related to thrombocytopenia.
2. Bowel angina Diffuse abdominal pain worse after meals





melena, hematochezia or positive test
for occult blood in the stool.
4. Hematuria Gross hematuria or microhematuria.
5. Age at onset
≤ 20 years
Development of first symptoms at
age 20 or less.
6. No medications Absence of any medications at onset
of disease which may have been a
precipitating factor.
The presence of any 3 or more of the 6 criteria yields a correct clas-
sification of HSP cases of 87.1%.
Data from Michel et al. 33
Medicine • Volume 93, Number 2, March 2014 Henoch-Schönlein Purpura in Northern SpainMarqués de Valdecilla, Santander, Spain) between January 1975
and December 2012. Special attention was paid to patients with
a diagnosis of vasculitis seen at the rheumatology, dermatology,
nephrology, pediatrics, and internal medicine divisions. In addi-
tion, we tracked information on vasculitis from the pathology
division. We assessed 417 patients seen at a single center who
were classified as having HSP according to the criteria proposed
by Michel et al33 (Table 1). Patients who did not fulfill these crite-
ria were not included in the study. These criteriawere based on the
American College of Rheumatology (ACR) database andmethod-
ology.33,34 HSP was pathologically confirmed in 110 cases by a
skin biopsy showing the characteristic histologic findings consis-
tent with leukocytoclastic vasculitis (Figure 1), including neutro-
philic infiltration; leukocytoclasia; fibrinoid necrosis into the
vessel wall of arterioles, capillaries, and postcapillary venules;FIGURE 1. Microscopic lower-power view of skin biopsy
of a patient with Henoch-Schönlein purpura showing
leukocytoclastic vasculitis. (H & E stain, original
magnification × 6). (Figure courtesy of Dr. González-Vela, MD,
PhD, Pathology Division.)
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Copyright © 2014 Lippincott Williams & Wilkins. Unauand red cell extravasation.16,28 The remaining 307 patients with-
out skin biopsy had typical nonthrombocytopenic symmetric pal-
pable purpura (Figure 2). In addition, all of them fulfilled the
criteria proposed by Michel et al.33
Ethical committee approval (Ethical Committee of Cantabria,
Spain) was obtained to perform studies on clinical and genetic
markers of patients with HSP.Clinical Definitions
We used the following definitions: 1) Classification by age
groups: as in previous reports,3,4,33,34 patients aged older than
20 years were considered adults and those aged ≤20 years were
considered children. 2) Precipitating events: a drug or a mild in-
fectious process (mostly an URTI) were considered as the prob-
able precipitating event of cutaneous vasculitis if they occurred
close (within the preceding week) to the onset of the skin
lesions. When a patient developed cutaneous vasculitis after an-
tibiotic or symptomatic treatment for a mild infection, both the
infection and the drug were considered possible precipitating
events. 3) Fever was defined as a temperature >37.7°C. 4) Joint
symptoms included arthralgia with or without joint effusion (ar-
thritis). 5) The presence of nephropathy was categorized as mild
or severe.4 Mild nephropathy included those patients with
microhematuria (≥5 red cells/high-power field) and/or protein-
uria that did not reach the nephrotic range. A patient was consid-
ered to have severe nephropathy if he or she had a) nephrotic
syndrome, defined as plasma albumin levels ≤25 g/L and either
proteinuria of 1 g/d per m2 of body surface area in children, or
proteinuria of >3.5 g/d in adults, with or without edema; or b)
when there was an acute nephritic syndrome defined as hematuria
with at least 2 of the following abnormalities: hypertension, in-
creased plasma urea or creatinine levels, and oliguria. Renal insuf-
ficiency was considered if the plasma creatinine was >125% of
the upper limit of normal. 6) Gastrointestinal manifestations in-
cluded either bowel angina (diffuse abdominal pain worsening
after meals) or gastrointestinal bleeding (melena, hematochezia,
or positive stool guaiac test). 7) Constitutional syndrome was
defined as asthenia and/or anorexia and weight loss of at least
4 kg. 8) A relapse was considered present when a patient previ-
ously diagnosed with HSP and asymptomatic for at least 1 month
had a new flare of cutaneous lesions or other systemic com-
plications (mainly renal disease) related to HSP.3FIGURE 2. Typical nonthrombocytopenic palpable
purpura in the lower extremities of a patient presenting with
Henoch-Schönlein purpura. (Figure courtesy of Dr. López Escobar,MD,
Dermatology Division.)
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In addition to a complete history and physical examination,
the following tests were performed routinely in most patients:
complete blood cell count, Westergren erythrocyte sedimenta-
tion rate (ESR) (mm/h), and routine urinalysis.
An immunologic profile was performed for most adults
with HSP, assessing rheumatoid factor (RF) (performed initially
by quantitative latex agglutination test, and later by nephelometry),
antinuclear antibodies (ANAs) (initially by indirect immunofluo-
rescence using rodent tissues as substrate, and more recently
using Hep-2 cells), and serum levels of C3 and C4 (initially by ra-
dial immunodiffusion, and more recently by nephelometry).
Antineutrophil cytoplasmic antibodies (ANCAs) were assessed
in patients diagnosed since 1992. They were initially performed
by indirect immunofluorescence on alcohol-fixed neutrophils,
and later, by ELISAwith purified proteinase-3 and myeloperoxidase.
Other determinations were cryoglobulins (the composition of
the cryoprecipitate was determined by double immunodiffusion
with specific antibodies) and immunoglobulins determined by
nephelometry. Additional tests, such as anti-DNA antibodies (by
immunofluorescence with Crithidia luciliae as substrate), blood
cultures, guaiac test for occult blood, and serology for hepatitis
B or C or human immunodeficiency virus (HIV) infection, were
performed only when indicated according to the clinical practice.
Anemia was defined as a hemoglobin level ≤110 g/L; leukocyto-
sis as a white blood cell count ≥11 × 109/L. ESR was considered
elevated when it was >20 or 25 mm/h for males or females,
respectively.3,35 Increased IgA levels were defined as total IgA
level >400 mg/dL.
As mentioned, skin biopsies were performed in most adults
with skin lesions, but in only a small number of children. Renal
biopsy was usually performed if there were signs suggestive of se-
vere renal disease, such as protein excretion above 1 g/d, an ele-
vated plasma creatinine concentration, or arterial hypertension.
In patients with HSP nephritis, light microscopy often disclosed
mesangial hypercellularity and increased deposition of extracellu-
lar matrix proteins (Figure 3). In these patients the pathognomonic
finding was the presence of prominent granular IgA deposits in
the mesangium by immunofluorescence microscopy.
Therapy, follow-up, recurrence, the need for dialysis or
kidney transplantation, and the final outcome were assessed in
all patients.FIGURE 3. Renal biopsy from a patient with Henoch-Schönlein
purpura nephropathy with mesangial glomerulonephritis
(H & E stain, original magnification × 100). (Figure courtesy of
Dr. González-Vela, MD, PhD, Pathology Division.)
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Data were first reviewed and then analyzed to retrieve the
following information: etiologic, clinical, laboratory, and histo-
pathologic features; treatment; and prognosis. Clinical, labora-
tory, and pathologic data were extracted from clinical records
according to a specifically designed protocol, reviewed for con-
firmation of the diagnosis, and stored in a computerized file. To
minimize entry error all data were double checked.
The statistical analysis was performed with the STATISTICA
software package (Statsoft Inc. Tulsa, OK). Results were expressed
as mean ± standard deviation (SD) for variables with a normal
distribution or as median and range or interquartile range (IQR)
(25th, 75th) for those not normally distributed. Continuous variables
(normally and not normally distributed) were compared with the
2-tailed Student t-test or the Mann-Whitney U test, respectively.
The chi-square test or the Fisher exact test was used for dichoto-
mous variables. Statistical significance was considered as p < 0.05.
RESULTS
Using the proposed criteria, 417 consecutive patients
(240 male and 177 female) were classified as having HSP. The
median age at disease diagnosis was 7.5 years (range, 8 mo–
87 yr; IQR, 5.3–20.1 yr). Table 2 summarizes the main demo-
graphic, etiologic, and clinical features of this series.
Demographic Data and Etiologic Factors
Most patients were children, aged ≤20 years (315 children/
102 adults). The disease was more prevalent in men and some-
what less frequent during the summer. At the clinical onset, 77
patients (18.5%) were taking drugs, most of them because of an
URTI. β-Lactams were the drugs most commonly associated
with this vasculitis. Hepatitis virus infection was found in 5
patients (4 hepatitis B and 1 hepatitis C). All patients were neg-
ative for HIV infection.
Clinical Features
At the onset of disease, HSP was characterized by the pres-
ence of skin lesions (55.9%), gastrointestinal involvement
(13.7%), joint symptoms (9.1%), nephropathy (24%), and fever
(6.2%). During the clinical course, cutaneous lesions were ob-
served in 100% of patients. Palpable purpura were found in
97.6%. Skin lesions were more frequent in the lower extremi-
ties (99%), although the upper extremities (31.9%) and trunk
(31.9%) were also involved. The median duration of the skin
lesions was 10 days (IQR, 6–15 d). Joint manifestations (mainly
arthralgia) occurred in 63.1% of patients with HSP. However,
arthritis (swollen joints) was observed on physical examination
in only 37.4% of patients. The most frequent joint pattern ob-
served was a nonerosive oligoarthritis affecting the knees and
ankles. During the course of HSP, gastrointestinal involvement
was present in 64.5% of patients. The main gastrointestinal
features were a typical colicky abdominal pain (64.5%), nausea
and vomiting (14.4%), melena and/or rectorrhagia (12.9%), and
positive stool guaiac test (10.3%). Renal involvement was ob-
served in 41.2% of patients, usually seen as mild nephropathy.
Nephrotic syndrome was observed in 4.8%, nephritic syndrome
in 2.9%, and renal insufficiency in 4.8%. Considering the worst
value of proteinuria in each patient with nephrotic syndrome,
the mean ± SD g/24 h was 7.9 ± 5.4 g/24 h. In patients with re-
nal involvement the mean ± SD worst value of serum creatinine
was 4.5 ± 3.1 mg/dL.
Fever was present in 85 (85/354; 20.4%) patients and con-
stitutional syndrome in 12 (12/215; 2.9%) patients. Other less
frequent manifestations were peripheral neuropathy in 8 (1.9%)© 2014 Lippincott Williams & Wilkins
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TABLE 3. Routine and Immunologic Laboratory Findings in
417 Patients With Henoch-Schönlein Purpura*
Leukocytosis 36.7% (128/347)
Anemia 8.9% (36/403)
Increased ESR 80.1% (105/131)
Increased IgA levels 31.7% (20/63)
Positive rheumatoid factor 4.9% (8/162)
Positive antinuclear antibodies 14.2% (25/176)
Positive ANCAs 0% (0/53)
Cryoglobulins 20.4% (19/93)
Low C3 and/or C4 7.9% (17/215)
*Routine laboratory tests were performed in most patients at the time
of disease diagnosis.
Values are percentages (no. positive/total no. tested).
Leukocytosis: leukocyte count ≥11 x 109/L.
Anemia: hemoglobin <110 gm/L.
Elevated erythrocyte sedimentation rate (ESR): ≥ 20 or 25 mm/h for
men or women respectively.
Increased IgA levels: serum IgA level >400 mg/dL.
TABLE 2. Main Demographic, Etiologic and Clinical
Features of a Series of 417 Patients With
Henoch-Schönlein Purpura
Number of patients 417























Nausea and/or vomiting 14.4
Melena and/or rectorrhagia 12.9









Abbreviations: URTI = upper respiratory tract infection. NSAIDs =
nonsteroidal antiinflammatory drugs.
*Mild nephropathy: microhematuria (≥ 5 red cell/hpf) and/or protein-
uria that did not reach the nephrotic range.
Severe nephropathy: a) nephrotic syndrome or b) nephritic syndrome.
Renal insufficiency: plasma creatinine was >125% of the upper limit
of normal.
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1 mononeuritis), scrotal edema in 2 patients, and lymphocytic
meningitis and epididymitis in 1 case each.
Laboratory Data
The main laboratory findings are shown in Table 3. Rou-
tine laboratory tests were done in most patients at the time
of disease diagnosis. Leukocytosis was present in 36.7%, and
anemia in 8.9% of patients. The mean ESR was 42.6±27 mm/h.
Serum IgA levels were increased in 31.7% of patients (20 of
63 tested). The mean ± SD value of IgAwas 323.8 ± 206.4 mg/dL.
Other immunologic tests such as RF and ANAs were generally© 2014 Lippincott Williams & Wilkins
Copyright © 2014 Lippincott Williams & Wilkins. Unaunegative, but in the few cases where they were positive, they were
at low titer and other diseases such as rheumatoid arthritis, sys-
temic lupus erythematosus, or other connective tissue disease were
excluded. In those patients with cryoglobulins the precipitate was
scarce (+/+++, or trace amounts), and none of them could be clas-
sified as having cryoglobulinemic vasculitis. ANCA antibody
tests were performed in patients who had been diagnosed since
1992. They were negative in all patients.
Treatment and Outcome
Half of the patients in the current series received drug ther-
apy. Corticosteroids were the most commonly used drugs (35%
of patients), generally prescribed because of persistent skin
lesions or visceral involvement, including severe abdominal pain,
gastrointestinal bleeding, or nephropathy. The median duration of
corticosteroid therapy was 1 month (IQR, 0.5–4 mo), and the me-
dian initial prednisone or equivalent dose was 30 mg/d (IQR,
25–45 mg/d). Cytotoxic drugs were given to 5% of patients either
as corticosteroid-sparing agents or as an additional therapy for
patients with severe renal involvement. Fourteen percent of pa-
tients were treated with nonsteroidal antiinflammatory drugs.
Five patients undergoing drug therapy had severe infections
(4 bacterial pneumonia and 1 herpes zoster infection).
After a median follow-up of 12 months (IQR, 2–38 mo),
complete recovery was observed in 83.2%. Persistent nephrop-
athy (renal sequelae) was found in 32 patients (7.7%); it was
mild in most cases (hematuria in 21 [5%] cases and hematuria
plus proteinuria in 5 [1%] cases). At last follow-up chronic (gen-
erally mild) renal insufficiency was observed in only 6 (1.5%)
patients. Relapses occurred in 31.9% of patients.
During the acute phase and then throughout the complete
course of the disease including the extended follow-up, dialysis
was required in 4 patients.
Clinical Subgroups
Henoch-Schönlein Purpura Distribution According to
the Age of Presentation
Significant differences in the epidemiologic, clinical, and
laboratory data; treatment; and outcome were found between
children and adults with HSP (Figure 4).www.md-journal.com 109
thorized reproduction of this article is prohibited.
FIGURE 4. Main clinical features of 417 adult and child patients with Henoch-Schönlein purpura at disease onset (A)
and when the disease was fully established (B). Data are expressed as percentages.
Calvo-Río et al Medicine • Volume 93, Number 2, March 2014The proportion of male patients was lower in children
(male/female, 54%/46%) than in adults (70%/30%) (p < 0.05).
A potential precipitating factor was more commonly found in
children than in adults (44% vs. 28%, respectively; p < 0.05);
true for both infections as a whole (43% vs. 23%, respectively;
p < 0.05), and, more specifically, associated with an URTI (39% vs.
14%, respectively; p < 0.05).
Regarding clinical manifestations, gastrointestinal involve-
ment (67.3% in children vs. 57.4% in adults; p < 0.05) and joint
manifestations (67% vs. 51%, respectively; p = 0.04) were more
common in children than adults. In contrast, nephropathy (84%
in adults vs. 27% in children; p < 0.01), nephrotic syndrome
(14.3% vs. 4.5%, respectively; p = 0.01), nephritic syndrome
(11.3% vs. 3.8%, respectively; p = 0.04), and renal insuffi-
ciency during the course of the disease (31% vs. 4%, respec-
tively; p < 0.01) were more frequently observed in adults than
in children.
As for laboratory findings, leukocytosis was more common
in children than in adults (41% vs. 24%, respectively; p < 0.01),
while anemia (15.7% in adults vs. 6.3% in children; p = 0.01),
elevated IgA (55% vs. 9%, respectively; p < 0.01) and positive
ANA (20% vs. 9.5%, respectively; p < 0.05) were more com-
mon in adults than in children (Figure 5).
Both skin (82% vs. 9%, respectively; p < 0.01) and renal
biopsy (27% vs. 10%, respectively; p < 0.01) were performed
more commonly in adults than in children.FIGURE 5. Main laboratory data of 417 patients with
Henoch-Schönlein purpura by age: adults and children. Data are
expressed as percentages.
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Patients With Henoch-Schönlein Purpura According
to the Presence of Nephropathy
As expected, residual nephropathy was more common at
last follow-up in the subgroup of patients who had renal in-
volvement at the time of disease diagnosis than in patients
who did not have the complication when the disease was diag-
nosed (18% vs. 1.7%, respectively; p < 0.001). Increased levels
of serum IgAwere more commonly observed in the subgroup of
patients with nephropathy than in those without renal involve-
ment (41.8% vs. 10%, respectively; p = 0.01). The percentage
of patients receiving drug therapy was higher in the group of
HSP patients with nephropathy than in those without (64.1%
vs. 35.8%, respectively; p < 0.001), including both corticosteroids
(52.5% vs. 28.7%; p < 0.001) and cytotoxic drugs (10.7% vs.
2.2%; p < 0.001). Regarding outcomes, complete recovery was
more frequent in the group of HSP patients without nephropathy
than in patients with nephropathy (97.1% vs. 74.7%; p < 0.001)
(Figure 6).DISCUSSION
As elegantly pointed out by Saulsbury,42 despite recent
progress in our understanding of HSP, its pathogenesis, clini-
cal spectrum, and treatment remain incompletely understood.41FIGURE 6. Main differences in laboratory data, treatment,
and outcome between patients with Henoch-Schönlein
purpura with and without nephropathy. Data are expressed
as percentages.
© 2014 Lippincott Williams & Wilkins
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Medicine • Volume 93, Number 2, March 2014 Henoch-Schönlein Purpura in Northern SpainSeveral factors may influence the great variability in clinical
features and outcome of HSP; namely, a) selection bias, because
some studies use data from nephrology series or use data from
selected series of children attending a major referral cen-
ter.23,24,35,36,39 b) The use of different criteria for the diagnosis
of HSP; specifically, in some series biopsy was required for the di-
agnosis of HSP while in others, mainly in typical cases of HSP in
children, skin biopsy or even kidney biopsy when the renal involve-
ment is mild was not performed.35 c) The absence of a standardized
therapeutic management, especially in cases of nephropathy.
Taking into account these considerations, in the present
study we assessed an unselected and large series of patients with
HSP. In an attempt to minimize selection bias, unlike other stud-
ies in which patients were studied at a single department, we in-
cluded all HSP patients seen at the rheumatology, pediatrics,
nephrology, dermatology and internal medicine divisions of a sin-
gle center. In addition, to draw solid conclusions on the severity
and the clinical spectrum of the disease, we included all patientsTABLE 4. Comparison Between the Present Series and Other Serie










No. of patients 417 122 85
Sex ♂ > ♀ ♂ > ♀ ♂ > ♀
Age, mean (years)
Global series 18.9 ND 17.4
Children/adults ND 6.6/40.5 ND
Children, n (%) 315 (75.5) 84 (68.8) 60 (70.6)
Adults, n (%) 102 (24.5) 38(31.2) 25 (29.4)
Precipitating event
URTI (%) 32.8 37.7 ND
Drugs intake (%) 18.5 9.8 18
Clinical features
Skin lesions (%) 100 100 100
Gastrointestinal (%) 64.5 85.2 67
Joint involvement (%) 63.1 54 50
Renal involvement (%) 41.2 36.8 60
Mild 34.1 23.7 ND
Severe 7.1 ND ND
Renal insufficiency 4.8 5.7 9.3
Laboratory findings
Leukocytosis (%) 36.7 63.9 ND
Anemia (%) 8.9 ND ND
High IgA (%) 31.7 52.4 5.6
Skin biopsy (%) 26.4 31.1 61.2
Treatment
Corticosteroids (%) 35 78.7 ND
Cytotoxic therapy* (%) 5 l2.4 ND
Prognosis
Complete recovery (%) 83.2 89.4 ND
Renal sequelae (%) 7.7 10.6 ND
Relapses (%) 31.9 32.8 ND
Abbreviations: ESR = erythrocyte sedimentation rate, URTI = upper resp
*Cytotoxic therapy: including azathioprine, cyclophosphamide, mycophe
© 2014 Lippincott Williams & Wilkins
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performed or not, since in the majority of children with typical
HSP—with or without mild renal involvement—biopsies were not
performed. We felt that including children without tissue biopsy
would reduce the risk of selection bias and provide readers with a
more accurate view of the actual clinical spectrum of the disease.
In line with the above, no previous selection according to
the age at the time of diagnosis was done. This fact allowed
us to further establish potential differences in the clinical spec-
trum and outcome between adults and children. This is of main
importance as previous studies have indicated a more severe
disease in adults with HSP.3,10,12,43,46
To address these issues we took advantage of the criteria
proposed by Michel et al.33 Classically, HSP was considered a
subgroup of hypersensitivity vasculitis.9 However, a subcom-
mittee of the American College of Rheumatology (ACR) de-
fined the criteria for the classification of several vasculitides













102 87 104 61
♀ > ♂ ♂ > ♀ ♂ > ♀ ♀ > ♂
ND ND ND ND
6.2/32.1 6.9/43.5 6.1/44.8 7/42
82 (80.4) 65 (74.7) 73 (70.2) 46 (75.4)
20 (19.6) 22 (25.3) 31 (29.8) 15 (24.6)
46 44.8 47.1 55.7
7.8 5.7 35.6 0
100 100 100 100
59.8 ≈ 60 75 65.6
67.6 ≈ 70 72.1 67.2
59.8 30 56.7 37.7
55.9 20.7 40.2 34.4
3.9 9.2 17.6 11.5
2.9 6.9 5.8 11.5
19.6 47.1 45.2 14.7
ND 2.3 7.7 1.6
ND 30.2 46.8 ND
ND 25.3 ND 41
ND 73.6 ND 14.7
ND ND ND 1.6
ND 94.3 80.8 67.2
ND 5.7 19.2 9.8




thorized reproduction of this article is prohibited.
Calvo-Río et al Medicine • Volume 93, Number 2, March 2014entities.34 Since HSP and hypersensitivity vasculitis share many
clinical-pathologic features, a high percentage of patients were
misdiagnosed. Therefore, based on the same database collected
by the ACR, Michel et al33 proposed a new set of criteria for differ-
entiating these 2 entities (see Table 1).
In the present study we performed a comparative analysis
of previous series of HSP that included all age groups, children
and adults (Table 4).
To the best of our knowledge, we describe here the largest
series of patients with HSP. We observed a predominance of male
patients that was in keeping with most series, although in some
reports females outnumbered males.22,46 The ratio of children to
adults was similar in all series, with the proportion of adults ap-
proximately one-quarter of HSP patients. Inmost series precipitat-
ing events were identified in approximately one-third of the cases,
although in 1 report precipitating events were described in more
than one-half of cases.22
The frequency of cutaneous involvement was similar in
all studies. However, differences in the prevalence of gastroin-
testinal manifestations have been described. Although in most
series gastrointestinal manifestations were reported in approxi-
mately 60% of cases, Lin et al29 found them in more than 80%
of patients.
Greater discrepancies regarding the frequency of nephritis
have been described. In the series by Hung et al,21 nephropathy
was present in only 30% of patients, while in the ACR series,34
renal involvement was described in 60% of the HSP patients.
With respect to laboratory findings, the highest frequency
of leukocytosis and high IgA serum levels was described in
the series by Lin et al.29 A plausible explanation for that may
be that the series included a high percentage of adults, and
adults generally exhibit more severe disease and consequently
more laboratory test abnormality than younger patients.
Concerning therapy, in the current series the percentage of
patients receiving cytotoxic agents was slightly higher than in
other series (see Table 4).
The frequency of renal sequelaewas higher in the series from
Galicia, Spain.12 This may be due to a higher frequency of nephri-
tis and more severe renal involvement than in other series.
When we split our cohort of HSP patients into 2 groups,
children and adults, as described in former reports,5,21,22,28 the
existence of a potential precipitating event, mainly URTI infec-
tion, was more common in children than in adults. As in former
studies, abdominal21,22,28,46 and joint involvement46 were also
more frequent in our series of children from northern Spain,
while the presence of nephropathy and severe renal involvement
was more common in adults.5,22,28,45 As previously reported, in
our series leukocytosis was more common in children,5,21,22,28
while anemia was more common in adults.21
Regarding the analysis of the subgroup of patients with
and without nephropathy, there are some differences between
the data obtained in our cohort and those previously reported.
As pointed out previously, renal involvement was less common
in children compared to adults.3,12,47 In the current series the
frequency of elevated serum IgA levels was higher in the sub-
group of HSP patients with renal involvement when compared
with the remaining patients. This was not the case in other stud-
ies.24 Nevertheless, data related to therapy in the current series
did not differ from data previously reported: patients with renal
involvement received more aggressive therapy, mainly corti-
costeroids, than other patients.
In conclusion, the results of the current study reinforce the
claim that although HSP is a typical vasculitis of children, a
quarter of cases are adults. The prognosis is generally favorable,
being mainly related to renal involvement.112 www.md-journal.com
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